Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-312024-04-01falseNo description of principal activity11truetruefalse 04361934 2024-04-01 2025-03-31 04361934 2023-04-01 2024-03-31 04361934 2025-03-31 04361934 2024-03-31 04361934 c:Director3 2024-04-01 2025-03-31 04361934 d:FreeholdInvestmentProperty 2025-03-31 04361934 d:FreeholdInvestmentProperty 2024-03-31 04361934 d:CurrentFinancialInstruments 2025-03-31 04361934 d:CurrentFinancialInstruments 2024-03-31 04361934 d:Non-currentFinancialInstruments 2025-03-31 04361934 d:Non-currentFinancialInstruments 2024-03-31 04361934 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 04361934 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 04361934 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 04361934 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 04361934 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-03-31 04361934 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-03-31 04361934 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2025-03-31 04361934 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2024-03-31 04361934 d:ShareCapital 2025-03-31 04361934 d:ShareCapital 2024-03-31 04361934 d:RevaluationReserve 2025-03-31 04361934 d:RevaluationReserve 2024-03-31 04361934 d:RetainedEarningsAccumulatedLosses 2025-03-31 04361934 d:RetainedEarningsAccumulatedLosses 2024-03-31 04361934 c:OrdinaryShareClass1 2024-04-01 2025-03-31 04361934 c:OrdinaryShareClass1 2025-03-31 04361934 c:OrdinaryShareClass1 2024-03-31 04361934 c:FRS102 2024-04-01 2025-03-31 04361934 c:Audited 2024-04-01 2025-03-31 04361934 c:FullAccounts 2024-04-01 2025-03-31 04361934 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04361934 c:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04361934 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure
Registered number: 04361934









PREMIUM HEALTHCARE PRODUCTS LIMITED

FILLETED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025







































 
PREMIUM HEALTHCARE PRODUCTS LIMITED
REGISTERED NUMBER: 04361934

BALANCE SHEET
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Investments
 5 
97,000
97,000

Investment property
 6 
320,000
320,000

  
417,000
417,000

Current assets
  

Debtors: amounts falling due within one year
 7 
-
12,407

Cash at bank and in hand
  
65,725
47,072

  
65,725
59,479

Creditors: amounts falling due within one year
 8 
(22,659)
(18,449)

Net current assets
  
 
 
43,066
 
 
41,030

Total assets less current liabilities
  
460,066
458,030

Creditors: amounts falling due after more than one year
 9 
(96,612)
(108,702)

  

Net assets
  
363,454
349,328


Capital and reserves
  

Called up share capital 
 11 
153,000
153,000

Revaluation reserve
  
64,060
64,060

Profit and loss account
  
146,394
132,268

  
363,454
349,328


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 30 December 2025.

M J Peck
Director

The notes on pages 3 to 8 form part of these financial statements.
Page 1

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
REGISTERED NUMBER: 04361934
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025


Page 2

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

Premium Healthcare Products Limited is a private company limited by shares and is incorporated in England and Wales.
The address of its registered office is Greenwood House, Greenwood Court, Skyliner Way, Bury St Edmunds, Suffolk, IP32 7GY.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Operating leases: the Company as lessor

Rental income from operating leases is credited to profit or loss on a straight-line basis over the lease term.

 
2.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.4

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 3

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.6

Investment property

Investment property is carried at fair value determined annually by the directors and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.

 
2.7

Associates and joint ventures

Associates and Joint Ventures are held at cost less impairment.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 4

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

  
2.11

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to the Statement of Income and Retained Earnings in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Balance Sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Balance Sheet.


3.


Employees




The average monthly number of employees, including directors, during the year was 1 (2024 - 1).


4.


Taxation

The company does not have a tax liability for the year due to the utilisation of tax losses brought forward.
The company has tax losses of £59,487 (2024 - £59,487) that are available for offset against future taxable trading profits as at 31 March 2025.







5.


Fixed asset investments





Investments in associates

£



Cost or valuation


At 1 April 2024
97,000



At 31 March 2025
97,000




Page 5

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

6.


Investment property


Freehold investment property

£



Valuation


At 1 April 2024
320,000



At 31 March 2025
320,000

The 2025 valuations were made by the directors, on an open market value for existing use basis.





If the Investment properties had been accounted for under the historic cost accounting rules, the properties would have been measured as follows:

2025
2024
£
£


Historic cost
255,940
255,940


7.


Debtors

2025
2024
£
£


Amounts owed by group undertakings
-
12,407



8.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank loans
9,931
9,931

Other taxation and social security
2,360
1,870

Other creditors
5,000
5,000

Accruals and deferred income
5,368
1,648

22,659
18,449


Page 6

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

9.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
96,612
108,702


Bank loans are secured on the investment property.


10.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year
9,931
9,931

Amounts falling due 2-5 years
39,723
39,723

Amounts falling due after more than 5 years
56,889
68,979

106,543
118,633



11.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



153,000 (2024 - 153,000) Ordinary shares of £1.00 each
153,000
153,000



12.


Related party transactions

Lalan Rubbers (Pvt) Limited:
The parent company and is registered in Sri Lanka.
At the year end there was a balance of £nil (2024 - £12,407) due to the company.
Gloveman Supplies Limited:
A fellow subsidiary company.
During the year the company charged rent and rates to Gloveman Supplies Limited to the value of £52,764 (2024 - £46,330). 

Page 7

 
PREMIUM HEALTHCARE PRODUCTS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

13.


Controlling party

The controlling party is Lalan Rubbers (Pvt) Limited (incorporated in Sri Lanka) and is regarded by the directors as being the company's ultimate parent company. The main address of the company is shown below:
95B, Zone A
Export Processing Zone
Biyagama
Malwana
Sri Lanka

The ultimate controlling party is L P Hapangama.


14.


Auditors' information

The auditors' report on the financial statements for the year ended 31 March 2025 was unqualified.

The audit report was signed on 31 December 2025 by Jonathan Moore ACCA (Senior Statutory Auditor) on behalf of Whitings LLP.

 
Page 8